The Danish Medicines Council recommends CSL Behring’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B
CSL Behring today announced that a positive recommendation for reimbursement of HEMGENIX has been released by the Danish Medicines Council for the treatment of patients with rare blood clotting disorder, haemophilia B opening the way to finalize a commercial contract with Amgros, the Danish procurement authority.1 Denmark is the first country in the Nordics to reimburse HEMGENIX.